Kazia Therapeutics (KZIA) Common Equity (2009 - 2025)

Kazia Therapeutics has reported Common Equity for 15 years, with the latest figure at -$5.3 million in Q2 2025.

• For the quarter ending Q2 2025, Common Equity rose 19.47% year-over-year to -$5.3 million; the trailing twelve-month figure through Jun 2025 stood at -$5.3 million (up 19.47% YoY), and the FY2025 full-year result was -$5.3 million, up 19.47% from the prior year.
• Common Equity for Q2 2025 stood at -$5.3 million, up from -$6.6 million in the prior quarter.
• The five-year high for Common Equity was $29.1 million in Q2 2021, with the low at -$6.6 million in Q2 2024.
• Historically, Common Equity has averaged $8.5 million across 5 years, with a median of $7.8 million in 2023.
• Annual changes were most pronounced in 2021 — Common Equity soared 214.84% — and 2024, when it plunged 181.97%.
• Kazia Therapeutics' Common Equity stood at $18.4 million in 2021, then tumbled by 58.73% to $7.6 million in 2022, then slumped by 54.94% to $3.4 million in 2023, then tumbled by 292.51% to -$6.6 million in 2024, then grew by 19.47% to -$5.3 million in 2025.
• The last three Common Equity figures came in at -$5.3 million (Q2 2025), -$6.6 million (Q2 2024), and $3.4 million (Q4 2023), per Business Quant data.